147
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment

, , , , &
Pages 35-44 | Published online: 28 Dec 2017

References

  • CalabreseJRHirschfeldRMFryeMAReedMLImpact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sampleJ Clin Psychiatry200465111499150415554762
  • ConnollyKRThaseMEThe clinical management of bipolar disorder: a review of evidence-based guidelinesPrim Care Companion CNS Disord201113410r01097
  • JuddLLAkiskalHSSchettlerPJThe long-term natural history of the weekly symptomatic status of bipolar I disorderArch Gen Psychiatry200259653053712044195
  • MerikangasKRJinRHeJPPrevalence and correlates of bipolar spectrum disorder in the world mental health survey initiativeArch Gen Psychiatry201168324125121383262
  • FryeMAPrietoMLBoboWVCurrent landscape, unmet needs, and future directions for treatment of bipolar depressionJ Affect Disord2014169suppl 1S17S2325533910
  • NierenbergAAMcIntyreRSSachsGSImproving outcomes in patients with bipolar depression: a comprehensive reviewJ Clin Psychiatry2015763e1025830453
  • UcokAGaebelWSide effects of atypical antipsychotics: a brief overviewWorld Psychiatry200871586218458771
  • ColomFVietaEMartinez-AranAReinaresMBenabarreAGastoCClinical factors associated with treatment noncompliance in euthymic bipolar patientsJ Clin Psychiatry200061854955510982196
  • GreenhouseWJMeyerBJohnsonSLCoping and medication adherence in bipolar disorderJ Affect Disord200059323724110854641
  • ScottJPopeMNonadherence with mood stabilizers: prevalence and predictorsJ Clin Psychiatry200263538439012019661
  • VietaEImproving treatment adherence in bipolar disorder through psychoeducationJ Clin Psychiatry200566suppl 12429
  • VelliganDISajatovicMHatchAKramataPDochertyJPWhy do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illnessPatient Prefer Adherence20171144946828424542
  • MagoRBorraDMahajanRRole of adverse effects in medication nonadherence in bipolar disorderHarv Rev Psychiatry201422636336625377611
  • BelzeauxRCorreardNBoyerLFondamental Academic Centers of Expertise for Bipolar Disorders (FACE-BD) CollaboratorsDepressive residual symptoms are associated with lower adherence to medication in bipolar patients without substance use disorder: results from the FACE-BD cohortJ Affect Disord201315131009101524051101
  • JohnsonFROzdemirSManjunathRHauberABBurchSPThompsonTRFactors that affect adherence to bipolar disorder treatments: a stated-preference approachMed Care200745654555217515782
  • KempDEManaging the side effects associated with commonly used treatments for bipolar depressionJ Affect Disord2014169suppl 1S34S4425533913
  • EaddyMGroggALocklearJAssessment of compliance with antipsychotic treatment and resource utilization in a Medicaid populationClin Ther200527226327215811492
  • WittinkMNMoralesKHCaryMGalloJJBartelsSJTowards personalizing treatment for depression: developing treatment values markersPatient201361354323420133
  • BridgesJFKinterETSchmedingARudolphIMuhlbacherACan patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks?Patient20114426727521995832
  • HauberABGonzalezJMGroothuis-OudshoornCGStatistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task forceValue Health201619430031527325321
  • Ng-MakDSRajagopalanKKleinmanLRobertsLRevickiDALoebelAQualitative study of patients’ preferences for bipolar depression treatmentISPOR 20th Annual International MeetingMay 16–20, 2015Philadelphia, PA
  • MedPanel [homepage on the Internet] Available from: www.medpanel.comAccessed December 12, 2017
  • CunninghamJLWernrothLvon KnorringLBerglundLEkseliusLAgreement between physicians’ and patients’ ratings on the Montgomery-Asberg Depression Rating ScaleJ Affect Disord20111351–314815321856017
  • SvanborgPAsbergMA comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS)J Affect Disord2001642–320321611313087
  • BechPClinical PsychometricsChichester, West Sussex, UKJohn Wiley & Sons, Ltd2012
  • HaysRDBjornerJBRevickiDASpritzerKLCellaDDevelopment of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global itemsQual Life Res200918787388019543809
  • Sawtooth Software Inc.The CBC/HB System for Hierarchical Bayes Estimation Version 5.0 Technical PaperSequim, WASawtooth Software Inc.2009
  • CellaDRileyWStoneAPROMIS Cooperative GroupThe patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008J Clin Epidemiol201063111179119420685078
  • LevitanBMarkowitzMMohamedAFPatients’ preferences related to benefits, risks, and formulations of schizophrenia treatmentPsychiatr Serv201566771972625772762
  • MoreyEThacherJACraigheadWEPatient preferences for depression treatment programs and willingness to pay for treatmentJ Ment Health Policy Econ2007102738517603148
  • WittinkMNCaryMTenhaveTBaronJGalloJJTowards patient-centered care for depression: conjoint methods to tailor treatment based on preferencesPatient20103314515720671803
  • BerkMBerkLCastleDA collaborative approach to the treatment alliance in bipolar disorderBipolar Disord20046650451815541066
  • RevickiDAHanlonJMartinSPatient-based utilities for bipolar disorder-related health statesJ Affect Disord2005872–320321016005983
  • KaneJMSharifZAAtypical antipsychotics: sedation versus efficacyJ Clin Psychiatry200869suppl 1183118484805
  • RamaekersJGBehavioural toxicity of medicinal drugs. Practical consequences, incidence, management and avoidanceDrug Saf19981831892089530538
  • YathamLNKennedySHParikhSVCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013Bipolar Disord201315114423237061
  • LoebelACucchiaroJSilvaRLurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled studyAm J Psychiatry2014171216016824170180
  • LoebelACucchiaroJSilvaRLurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled studyAm J Psychiatry2014171216917724170221
  • CalabreseJRKeckPEJrMacfaddenWA randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depressionAm J Psychiatry200516271351136015994719
  • ThaseMEMacfaddenWWeislerRHEfficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)J Clin Psychopharmacol200626660060917110817